Parkinson's Disease

Parkinson's disease isn't explicitly mentioned in the curriculum, falling under the generic category of patients with neurological disease.

Nevertheless it was a CRQ in 2020 (71% pass rate), with lost marks on the pharmacology of Parkinson's drugs including the features of medication withdrawal.

A repeat CRQ in 2023 (59% pass rate) saw candidates fall down on the pharmacology again, namely drugs which can be given non-enterally and (again) withdrawal.

Resources


  • Idiopathic Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease, affecting >1% of those over 65 years
  • It poses perioperative challenges owing to the multi-system effects of the disease and the need to ensure uninterrupted anti-Parkinsonian medication delivery
  • Patients have higher rates of perioperative complications, critical care admission and mortality, as well as longer hospital stays

  • Loss of dopaminergic neuronal pathways in the pars compacta of the substantia nigra
  • There is considerable dopaminergic neuronal reserve, so symptoms only manifest when 70% of dopaminergic neurones are lost
  • The precise mechanism for the degeneration is unknown, although age is the single most consistent risk factor

Dopamine production

  • Dopamine is a naturally occurring catecholamine hormone and neurotransmitter
  • It is produced in a series of steps:
    1. The amino acid phenylalanine is metabolised by phenylalanine hydroxylase to tyrosine, mainly in the liver
    2. Tyrosine is actively concentrated in the cytoplasm of adrenergic neurones
    3. Tyrosine is metabolised to DOPA by the enzyme tyrosine hydroxylase, which is the rate-limiting step in the process
    4. DOPA is metabolised to dopamine by DOPA-decarboxylase

  • The classic Parkinsonian motor symptoms are a triad of:
    1. Bradykinesia
    2. Muscle rigidity
    3. Asymmetric resting tremor

Other symptoms in Parkinson's disease

Constitutional Motor Neuropsychiatric Autonomic symptoms
Fatigue Altered gait Depression/anxiety Postural hypotension
Sleep disturbance Micrographia Cognitive disturbance Sialorrhoea
Constipation Dysphagia Dementia Urinary dysfunction
Chronic pain Soft speech (hypophonia) Hallucinations/psychosis Sexual dysfunction
Expressionless (mask-like) face Impulse control disorders Excessive sweating
Postural instability

'On' and 'Off' periods

  • Many patients fluctuate between 'On' periods (good symptom control) and 'Off' periods (return of tremor, rigidity and bradykinesia as medication wears off)
  • 'Off' states can also cause anxiety, autonomic symptoms and painful dystonia
  • Missed or delayed doses precipitate 'Off' state deterioration: freezing, falls, swallowing difficulty, poor cough, respiratory muscle rigidity and impaired secretion clearance

Differential diagnosis of Parkinsonian features

  • Idiopathic Parkinson's disease (85% of those with Parkinsonism)
  • Parkinson's plus syndromes (see below)
  • Vascular e.g. multi-infarct disease, arteriosclerosis
  • Wilson's disease
  • Iatrogenic e.g. reserpine, anti-dopaminergic drugs such as prochlorperazine
  • Infectious e.g. post-encephalitis
  • Trauma e.g. dementia pugilistica
  • Metabolic e.g. hypoparathyroidism
  • Neoplastic e.g. space-occupying lesion

Parkinson's plus syndromes

  • These are characterised by poor or absent levodopa response, more rapid progression, earlier and more severe multisystem involvement, and shorter survival
  • Frailty, dysphagia and speech impairment occur earlier and are more severe
  • Levodopa should still not be withdrawn for prolonged periods as the degree of efficacy of levodopa sometimes only becomes apparent upon withdrawal
  1. Multiple system atrophy (MSA)
    • Early, marked autonomic dysfunction (orthostatic hypotension, bladder and bowel)
    • Stridor, vocal cord dysfunction and sleep-disordered breathing
    • GA may be complicated by difficult airway, hypotension and lack of response to atropine

  2. Progressive supranuclear palsy (PSP)
    • Early falls, vertical gaze palsy and cognitive impairment
    • Cervical dystonia may complicate airway management

  3. Corticobasal syndrome (CBS)
    • Highly asymmetric limb rigidity and apraxia, which complicate positioning and monitoring

  • Pharmacological management aims to manage symptoms via supplementation of CNS dopamine
  • Over 80% of patients take levodopa
  • Dopaminergic medications are time critical
Class Examples Common side-effects
Dopamine precursor +
DOPA decarboxylase inhibitor
Co-careldopa (Sinemet)
Co-beneldopa (Madopar)
N&V
Orthostatic hypotension
Dyskinesia
Hallucinations
Dopamine agonist Pramipexole
Ropinirole
Apomorphine (subcutaneous)
Rotigotine (transdermal)
Cabergoline (ergot)
Nausea
Highly emetogenic (apomorphine)
Impulse control disorders
Orthostatic hypotension
Somnolence
Valve regurgitation (ergot derivatives)
MAO-B inhibitor Selegiline
Rasagiline
Safinamide
Headache
Arthralgia
Serotonin syndrome with serotonergic drugs
COMT inhibitor Entacapone
Opicapone
Tolcapone
Dark urine
NMDA antagonist Amantadine Confusion
Hallucinations

Device-aided therapies

  • Used in advanced disease with severe motor fluctuations:
    • Subcutaneous apomorphine infusion or pen (APO-go, Dacepton)
    • Co-careldopa intestinal gel (Duodopa) via PEJ or PEG-J
    • Foslevodopa-foscarbidopa continuous subcutaneous infusion (Produodopa)
  • Continue the usual infusion regimen perioperatively wherever possible
  • Do not stop or alter pump settings without advice from the Parkinson's specialist team
  • Patients should bring enough drug and equipment for the whole admission, as these may not be stocked locally
  • The pumps are not MRI compatible

Non-enteral and alternative routes

  • Plan an alternative route whenever the patient will be nil by mouth for more than one scheduled dose or more than 4 hours, whichever is shorter
  1. NG/NJ tube: first-line
    • Levodopa is absorbed mainly in the jejunum, so this is preferred if the gut is functioning
    • Co-beneldopa (Madopar) dispersible tablets are the preparation of choice although immediate release co-careldopa can be dispersed off-label
    • Modified release (CR, MR, XL, PR) preparations must never be crushed or given via a tube and one should convert to immediate release first
    • When converting from modified release levodopa, consider reducing the total daily dose by 25-30%
    • Pause enteral feed around levodopa doses as protein competes with levodopa absorption

  2. Rotigotine transdermal patch: second-line
    • Used where the enteral route is unsuitable e.g. GI surgery, ileus
    • Dose equivalence is only approximate (calculated with tools such as PDMedCalc), and it may not be potent enough for those on high-dose regimens
    • Peak effect at approximately 12 hours; for elective cases, apply at 7pm the evening before surgery after the last oral dose
    • Dopaminergic side-effects: nausea, hallucinations, agitation and delirium, so 'start low, go slow' in the cognitively impaired
    • Contains aluminium so should remove before MRI or cardioversion

  3. Apomorphine
    • Continue in those already established on it, as the subcutaneous route is unaffected by NBM status
    • Highly emetogenic and can cause profound hypotension
    • Ondansetron and other 5-HT3 antagonists are absolutely contraindicated alongside it (severe hypotension, QT prolongation)

Parkinsonism-hyperpyrexia syndrome (PHS)

  • A life-threatening acute hypodopaminergic state, clinically similar to NMS, with mortality up to 20% if untreated
  • Usually precipitated by interruption, withdrawal or reduced absorption of dopaminergic drugs, particularly levodopa
  • Other causes include administration of dopamine-blocking drugs, infection, dehydration and deep brain stimulator failure

  • Red flags (any one triggers emergency assessment):
    • Fever >38.0°C with rigidity or worsening 'Off' state
    • Altered consciousness or rapidly worsening confusion
    • Autonomic instability: tachycardia, labile BP, tachypnoea, sweating
    • Unable to take oral Parkinson's medication for more than one scheduled dose

  • Management:
    • Escalate as an emergency and seek neurology advice
    • Reinstate dopaminergic medication without delay; levodopa is the cornerstone, via NG tube if needed, then rotigotine or apomorphine
    • IV fluids, active cooling and benzodiazepines for fever and agitation
    • Check CK, renal function, electrolytes and clotting
    • ICU for complications: rhabdomyolysis, AKI, DIC, aspiration pneumonia

Dopamine agonist withdrawal syndrome (DAWS)

  • Follows reduction or withdrawal of a dopamine agonist, with a higher risk if high doses or impulse control disorders are present
  • Anxiety, panic, dysphoria, generalised pain, sweating, orthostatic hypotension, intense drug craving and suicidal ideation
  • Refractory to levodopa and requires reinstatement of the withdrawn agonist

Differential diagnoses

  • Hyperthermia under anaesthesia should not be attributed to PD until other causes have been considered
  • PD does not increase susceptibility to malignant hyperthermia
  • Where PHS and MH are both possible, reinstate dopaminergic therapy without waiting for diagnostic certainty as it causes no harm in MH but delay is dangerous in PHS

Condition Distinguishing features Dopaminergic therapy
PHS Rigidity, worsening 'Off', fever, confusion after missed doses Reinstate/increase
Dyskinesia-hyperpyrexia syndrome Prolonged, exhausting generalised dyskinesia; rhabdomyolysis Reduce
Serotonin syndrome Clonus, hyperreflexia, diarrhoea; MAO-B inhibitor + serotonergic opioid Do not increase
Stop offending drug
Malignant hyperthermia Volatile or suxamethonium exposure; rise in EtCO2 precedes temperature Neither causes nor treats
Give dantrolene
DBS malfunction Sudden worsening tremor, rigidity or dyskinesia; battery depletion Urgent DBS team review


  • Implanted leads stimulate the subthalamic nucleus, globus pallidus internus or thalamus, connected to a pulse generator usually sited in the chest wall
  • DBS augments rather than replaces medication, so usual Parkinson's drugs must continue

Pre-operative

  • Contact the patient's DBS team to obtain the device ID card, model, generator location, settings, MRI compatibility and severity of symptoms when switched off
  • Consider skull and chest X-ray to delineate the path of the leads

Intra-operative

  • Monopolar diathermy must not be used due to the risk of intracranial heating and burns along the leads
  • Bipolar diathermy is safe, and PlasmaBlade is an alternative
  • Keep DBS switched on for most surgery unless directed otherwise by a specialist DBS team
  • DBS can cause ECG artefact mimicking VT; confirm monitoring is interpretable before induction
  • If the device is switched off for the procedure, turn it on before emergence and consider an intra-operative NG tube for drug delivery in long cases
  • Emergency surgery with no DBS team: leave it on and do not attempt to switch it off

Post-operative

  • Ensure the device is switched back on using the patient's controller
  • Perform a neurological examination and consider a device check

Airway

  • Upper airway dysfunction from laryngeal and pharyngeal bradykinesia or dyskinesia
    • Retained secretions, atelectasis and aspiration
    • Higher chance of post-extubation laryngospasm, often associated with thick saliva

  • Obstructive sleep apnoea in 20-66%
  • Fixed flexion deformity of the neck (antecollis) may impair laryngoscopic view

Respiratory

  • Respiratory muscle rigidity, bradykinesia or dyskinesia can cause a restrictive pulmonary deficit
  • Ineffective cough with dysphagia makes aspiration pneumonia a leading cause of death
  • In time leads to pulmonary hypertension

Cardiovascular

  • Cardiovascular dysautonomia affects over 80%: orthostatic and postprandial hypotension, supine hypertension
  • Patients are prone to intra-operative hypotension and have altered responses to vasopressors
  • Associated with PR and QT prolongation, arrhythmias, heart failure and coronary artery disease
  • Ergot dopamine agonists (e.g. cabergoline) cause valvular regurgitation; consider echocardiography

Neurological

  • Higher incidence of post-operative delirium (60%) and hallucinations
  • Dementia develops in up to 50% within 10 years of diagnosis
  • Chronic pain is common (66-89%), and pain thresholds are lowered
  • Lower anaesthetic requirements

Renal

  • Increased risk of post-operative UTI, a common precipitant of delirium and neurological deterioration
  • Higher incidence of AKI

Gastrointestinal

  • Dysphagia affects ~30% at hospital presentation and >80% as the disease progresses; it is often silent
  • Sialorrhoea results from impaired swallowing rather than excess saliva production
  • Increased prevalence of GORD and gastroparesis
  • Post-operative ileus may impact on absorption of anti-Parkinsonian drugs
  • Constipation is near universal
  • Dopaminergic anti-emetics are contra-indicated

MSK

  • Frailty and falls are common
  • Immobility increases VTE and pressure ulcer risk
  • Rigidity and abnormal posture make positioning more difficult

Perioperative management of the patient with Parkinson's Disease


Assessment

  • Comprehensive pre-assessment, especially as many PD patients will be elderly and frail with comorbid disease
  • Document an exact medication regimen with timings, including any device-aided therapy or DBS
  • Document baseline cognition and function
  • Swallow assessment including tablet swallowing although N.B. the standard water swallow test alone is unreliable in PD
  • Nutritional screening e.g. MUST
  • Note MAO-B inhibitor use, including rasagiline or selegiline in the preceding 2 weeks

Optimisation and planning

  • Involve the Parkinson's specialist team early for moderate to severe disease, complex regimens and device-aided therapies
  • Prehabilitation with physiotherapy for major surgery
  • Shared decision-making, including rehabilitation expectations, treatment escalation plans and resuscitation decisions
  • Discuss the possibility of waking in an 'Off' state, and the plan to manage it
  • Begin discharge planning

Scheduling and fasting

  • First on a weekday morning list to minimise fasting and allow predictable drug administration
  • Consider a day-case pathway to keep close to the normal routine
  • Fasting is not a reason to omit PD medication: continue oral drugs and clear fluids (up to 170 ml/hr) using SipTilSend until sent for
    • Exceptions: oesophageal or gastric surgery, obstructing GI lesions, and patients with dysphagia, significant gastroparesis or other aspiration risk factors
  • Plan an alternative route of administration in advance if NBM is expected beyond one dose or 4 hours

Monitoring and access

  • AAGBI, acknowledging that:
    • NIBP may be affected by tremor and motion artefact
    • ECG may be affected by tremor causing motion artefact, which may look like AF
    • ECG may be affected by sweating from autonomic dysfunction, which may impair electrode placement
    • DBS can produce ECG artefact mimicking VT
  • Lower threshold for an arterial line to manage dysautonomia
  • Consider processed EEG, as anaesthetic requirements are lower
  • Core temperature monitoring to avoid hypothermia and detect early PHS
  • Avoid urinary catheterisation where possible
  • Monitor fluid status to avoid dehydration and post-operative orthostatic hypotension

Anaesthetic technique

  • Regional anaesthesia is recommended where appropriate
  • There is no single anaesthetic regimen, and the choice depends on the patient and the surgery

Regional and neuraxial anaesthesia

Advantages Disadvantages
Avoids airway manipulation Technically difficult with tremor and rigidity
Able to monitor Parkinsonian symptoms intra-operatively Tremor persists outside the blocked area, which can impair surgery and monitoring
Can give oral medication intra-operatively Positioning difficulties from rigidity
Early return to post-operative oral intake Cognitive impairment may limit cooperation
Reduced use of systemic opioids (may decrease GI function) Neuraxial hypotension, especially with autonomic dysfunction
No need for NMBA or reversal agents
Reduced risk of delirium

General anaesthesia

Advantages Disadvantages
Abolishes tremor and dyskinesia Several drugs can worsen PD
May protect the airway in severe dysphagia Worsens cough, swallow and respiratory function; ↑ aspiration pneumonia
PONV may prevent oral PD medication
Increased risk of delirium

  • If GA is used:
    • Consider RSI with dysphagia, significant gastroparesis or other aspiration risk
    • Consider glycopyrrolate for excessive sialorrhoea; it does not cross the BBB, unlike atropine, though it thickens saliva
    • Consider intubation where sialorrhoea is excessive
    • Ensure suction is available and be prepared for laryngospasm at extubation
    • Aim for early extubation to allow neurological assessment
  • For surgery over 3 hours, consider an NG tube so PD medication can be given intra-operatively

Drugs

Agent Notes
Propofol Preferred induction agent as it suppresses tremor and is anti-emetic.
TIVA is advantageous for the same reasons.
Rarely causes dyskinesia
Thiopentone Theoretical worsening of PD symptoms, though used without harm
Ketamine Use with caution due to sympathomimetic interaction with levodopa and ↑ salivation.
Low dose may be a useful adjunct when PD doses are missed
Volatiles Sevoflurane and isoflurane are safe
Lower MAC-awake for sevoflurane.
Halothane historically avoided due to levodopa-induced arrhythmias
Dexmedetomidine Safe
Useful sedative for DBS procedures
Non-depolarising NMBA Safe.
Reverse with sugammadex in preference to neostigmine-glycopyrrolate to avoid thickened secretions
Opioids Use with caution.
Large doses of fentanyl/alfentanil and high-rate remifentanil cause rigidity
Patients demonstrate increased sensitivity to remifentanil.
Avoid tramadol and pethidine with MAO-B inhibitors

MAO-B inhibitor interactions

  • Applies to patients taking MAO-B inhibitors, or who have taken rasagiline or selegiline in the preceding 2 weeks; increased risk of:
    • Hypotension with inhalational and intravenous anaesthetics
    • Hypertensive crisis with noradrenaline, metaraminol, adrenaline, ephedrine, dobutamine, dopamine and phenylephrine
    • Bradycardia with fentanyl, alfentanil, remifentanil, propofol, neostigmine or suxamethonium
    • Serotonin syndrome with serotonergic opioids

Recovery

  • Check the patient's own PD medication has come with them and give doses on time
  • Check any rotigotine patch is still in place, as skin preparation and transfers can dislodge it
  • No unsupervised fluids until swallow has been assessed by trained staff
  • Early delirium screening in a quiet, low-stress environment
  • Continue core temperature monitoring
  • Consider HDU/enhanced care given altered responses to drugs from autonomic dysfunction

Medication

  • Give all doses within 30 minutes of the prescribed time; a late dose is better than an omitted one
  • Return to usual enteral PD drugs ASAP; otherwise NG/NJ levodopa, then transdermal rotigotine
  • Prescribe and plan overnight doses explicitly, as these are the most commonly missed
  • Pharmacist review of all PD patients' drug charts
  • Remain vigilant for PHS and DAWS if there have been any problems with drug administration

Analgesia

  • Multimodal, opioid-sparing approach: regular paracetamol and NSAIDs first-line, plus regional techniques where possible
  • Distinguish surgical pain from 'Off' state dystonic pain, which responds to dopaminergic therapy rather than analgesia
  • Facial masking blunts pain expression, so assess pain by function and verbal confirmation
  • PCA may be difficult to use due to rigidity/tremor
  • Use small doses of immediate release opioids, and co-prescribe laxatives

Serotonin syndrome risk Opioids With MAO-B inhibitor
Lower Morphine, codeine, dihydrocodeine, buprenorphine, hydromorphone, alfentanil, remifentanil Preferred
Intermediate Fentanyl, oxycodone, methadone, tapentadol Use with vigilance
Higher Tramadol, pethidine Contraindicated

Delirium

  • Post-operative delirium (60%) and hallucinations are more common
  • Screen daily with a validated tool e.g. 4AT, and distinguish hypoactive delirium from an 'Off' state
  • Avoid deliriogenic drugs where possible, including anticholinergics and opioids
  • If drug treatment is needed for safety:
    • Avoid dopamine-blocking antipsychotics e.g. haloperidol, chlorpromazine, olanzapine
    • Lorazepam or quetiapine are options; clozapine only under specialist supervision

Anti-emetics

  • Give prophylactic anti-emetics, as PONV delays return to oral medication
  • Never give centrally acting dopamine antagonists
Safe Do not use
Ondansetron/granisetron* Metoclopramide
Domperidone (doesn't cross BBB)** Butyrophenones (haloperidol, droperidol)
Cyclizine Phenothiazines (prochlorperazine, promethazine, chlorpromazine)
Dexamethasone
  • *QT prolongation; absolutely contraindicated with apomorphine
  • **QT prolongation and sudden cardiac death risk in over 60s; maximum 10 mg TDS for up to one week, avoid with apomorphine
  • Cyclizine or dexamethasone are the alternatives in patients on apomorphine

Rehabilitation and discharge

  • Drinking, eating and mobilising (DrEaMing) within 24 hours unless contraindicated
  • Early physiotherapy and occupational therapy; cueing strategies help overcome freezing
  • Falls risk assessment, regular laxatives and early removal of catheters and drains
  • On discharge, communicate swallow status, any medication or route changes and follow-up to the patient, carers and GP